Tiu et al; “IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial”; Nature Communications, 2026
https://www.nature.com/articles/s41467-026-77552-7
del Pozo et al: “Discovery of Novel Oral Covalent Inhibitors Targeting Active GTP-Bound KRASG12C with Potent Antitumor Activity”, J. Med Chem. 2026
https://doi.org/10.1021/acs.jmedchem.6c01318
Gao et al: “Altered Inflammatory Signature in a C9ORF72 -ALS iPSC-Derived Motor Neuron and Microglia Coculture Model”, Glia. 2026
https://doi.org/10.1002/glia.70084
Sheth et al: “Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays”, Clin Chem Lab Med. 2025/2026
https://doi.org/10.1515/cclm-2025-0610
Callahan, et al: “The Discovery of GSK3227634: A Potent Inhaled Inhibitor of the KEAP1/NRF2 Protein-Protein Interaction for the Treatment of COPD”, J. Med Chem. 2026
https://pubs.acs.org/jmcmar/article/69/17/20859/5256079/The-Discovery-of-GSK3227634-A-Potent-Inhaled
Ma et al: “From KRASG12D to Pan-KRAS Inhibitors ─ A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design”, J. Med Chem. 2026
https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c03662
Twigg et al: “Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective” J. Med Chem. 2025
https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c02894
© Astex Pharmaceuticals
All rights reserved
